Delhi to examine 'weak regulation' of clinical trials

view gallery VIEW GALLERY

Trial and Error - Part 3: Indian authorities admit to the failings exposed by The Independent's investigation into drug tests

Delhi

Indian authorities have claimed they plan to tighten regulations over the way medical trials are conducted in the country and address some of the concerns highlighted in The Independent's investigation.

As campaigners in India and around the world repeated their call for better oversight, official sources admitted that weak regulation was a problem that needed to be tackled by the Drug Controller General of India (DGCI), the body charged with overseeing and regulating trials.

Last week, Dr V G Somani was appointed to head the body, which is part of the Ministry of Health and Family Welfare. The Health Minister Ghulam Nabi Azad failed to respond to inquiries.

A source within the drugs control department said its priorities would be the establishment of clearer guidelines – especially for dealing with adverse reactions to drugs taken during a trial – a focus on affordable medicine for India, and the development of research and development. "I don't think you can say the oversight was a failure. But it was weak oversight," said the source, who asked not be identified given the sensitivity of the issue.

In regard to ethical committees, the supposedly independent bodies that oversee and monitor trials, the source added: "The committees have to be made more accountable, by law." But the source said the committees' ability to oversee was limited. "They cannot inspect every day," the source added.

Sandhya Srinivasan, executive editor of the Indian Journal of Medical Ethics, said there was a pressing need for more effective oversight, given the abuses that have come to her attention. "In theory much of it can be addressed by regulation," she said. "Another larger concern is that effective, life-saving drugs tested in India are not available in India at anywhere near an affordable price."

Dr Anand Rai, a physician turned whistle-blower from Indore, where he exposed trials that a police inquiry said breached ethical guidelines, also said it was important the authorities focused on the trials of drugs designed to tackle diseases that are common in India, such as malaria and dengue. He also called for better regulation of ethical committees.

Brinda Karat, an opposition MP who has led calls for better oversight, said changes made to legislation that loosened regulations "must be reviewed in the light of the experience of the last six years. Also, the pending bill on regulation must be placed before the parliament". She added: "Strong action [must be taken] on the cases you have written about."

Some say there must be a complete overhaul. Dr Chandra Gulhati, editor of the Monthly Index of Medical Specialties and the man who has collated much of the data regarding drug trials in India, said many believed the changes made in 2005 had helped foreign drug companies by reducing costs and providing easy access to trial subjects, but had provided little benefit to India.

"What does India get as a nation?" he said. "I believe the issue is not of tightening the rules but revisiting the entire process of unconditional liberalisation. When India permits British Airways to start a service to India, Indian carriers in return get the same facility. This is reciprocal. In the drug field there is just one-way traffic."

Europe: MEPs target companies using 'guinea pigs' overseas

An influential group of MEPs have vowed to stamp out unethical clinical trials by forcing European regulators to take more robust action against drug companies guilty of violations.

The MEPs are urging a key European committee to hold emergency discussions amid growing evidence of ethical abuses in developing countries. The European Medicines Authority (EMA) has been accused of failing to enforce existing laws that stipulate only drugs tested ethically, to international standards, should be licensed in Europe.

The EMA, responsible for approving new drugs in Europe, told The Independent that the globalisation of clinical trials posed a "huge challenge" that needed more resources and better cooperation from the pharmaceutical industry.

Dr Peter Liese, German Christian Democratic MEP, said rejecting just one unethically tested drug from the European market would serve as a "powerful message" to the whole industry. "We have a big problem and we need to do better," he said. "But it is not a question of new laws, it is about implementing existing ones."

Margrete Auken, Danish Green Party MEP, said Europe must treat unethical clinical trials with the same gravity as organ trafficking and called for companies to be "named and shamed".

There are almost 120,000 clinical trials currently taking pace in 178 countries. But only 36 of those countries have effective drug regulators, including just one in Africa, one in Latin America and three in Asia. This means Western regulators, including the EMA and the US Food and Drug Administration, know that huge numbers of clinical trials are taking place without adequate supervision. The EMA has never rejected a new drug solely on the basis of ethical violations.

Critics say that the watchdog's current approach is inadequate. "The EMA must start asking drug companies for information about how they safeguarded the safety of participants before they grant authorisation," Annelies den Boer, of the Dutch health NGO Wemos, said. "Europe is the second-largest drug market in the world, so we need to send a strong signal to companies that they cannot get away with it."

Dr Amit Sengupta, from Health Action International, said: "The [Western] regulators are becoming wary about poorly regulated countries not because of the unethical practices, but because they are worried about quality of the data which could harm their own patients."

In the UK, Lord Leslie Turnberg, former NHS doctor and chair of the All Party Parliamentary Group on Medical Research, said he would consider investigating the issues raised by The Independent. British and US lawyers are also considering the evidence to determine whether civil cases can be brought.

Nina Lakhani

Polio vaccine: An ethical dilemma

A new vaccine tested in Indore has emerged as a key tool in India's battle against polio. And in the process it has shown how complex the questions over ethical drug trials are bound to be.

Some of the research on the medication was carried out at the Maharaja Yashwantrao hospital in Indore, the same one that has had new trials suspended amid allegations that a small group of doctors conducted trials in breach of regulations. (The doctors and the hospital deny the charges.) The vaccine is important because it can immunise children against two key strains of the virus in a single dose. The long-running struggle to eliminate polio in India is looking better than it ever has: last month officials said there had been only one reported case this year.

Dr Hemant Jain, a US-trained paediatrician who was involved in testing the vaccine and who denied there had been a breach of guidelines, claimed the controversy had put back drug trials in India by 10 years. "The WHO came to us with a request to test a new vaccine. Credit has been given to this new vaccine and 75 per cent of the work was done in Indore," he said.

Breaking the rules A worldwide epidemic

China

There are 2,520 trials for China currently on the US registry, but it is almost impossible to ascertain the regulatory situation. Researchers working for the Dutch NGO Wemos tracked down trial participants by hanging around hospitals and university campuses where recruitment posters are common.

Ms Liu, 47, a poor farmer from near Beijing, agreed to take part in a trial for an anti-cancer drug by a Chinese company manufacturing traditional herbal medicines. She had been diagnosed with brain and lung cancer and could not afford treatment. The hospital conducted a lottery because so many poor people were desperate for the free care. "I didn't really understand what a clinical trial means," she said. "But we are poor farmers and the most important thing for us is to save money... I had the treatment a few months ago but I have no idea if the medicine worked. I am still very ill."

Poland

Data from 167 pivotal trials was submitted from Poland to the EMA between 2005 and 2009, making it the sixth most popular European destination at that time.

Research by the NGO Wemos published in 2010 found CROs and drug firms actively recruiting vulnerable people, such as the homeless, in return for small payments.

In one case, Ania, 34, a successful businesswoman from Warsaw, volunteered for a fertility drug trial sponsored by a US company. She fell pregnant but miscarried after six weeks, and signed up again three months later. In the meantime her husband, a doctor, obtained the medical reports and found that the foetus had been severely deformed. "The CRO was very reluctant to let us get out of the [second] contract... if we said anything or anything showed up in the media, they would sue us." Ania is in a legal battle to get out of the confidentiality agreement.

Brazil

With only one language and a large, ethnically diverse population concentrated in major cities, Brazil is the most popular destination for clinical trials in South America. There are 2,520 trials currently listed on the US clinical trials registry, partly explained by the 150 million uninsured Brazilians who are desperate to gain access to medical treatment.

Brazil, like India, has recently relaxed regulatory systems to speed up the approval of clinical trials, allowing CROs to operate without accreditation – registration with the chamber of commerce is enough to start testing drugs on humans. At least 26 CROs operate in Brazil, mostly in Sao Paulo, including eight of the top 10 multinationals.

Independent oversight by regulatory authorities and ethics committees in Brazil "leaves a lot to be desired", the NGO Somo has warned.

* From tragedy to travesty: Drugs tested on survivors of Bhopal
* Without consent: how drugs companies exploit Indian 'guinea pigs'
* Leading article: Drugs firms must not prey on poverty
* Drugs policy advisor under fire over links to pharmaceutical company

PROMOTED VIDEO
Life and Style
ebookA wonderful selection of salads, starters and mains featuring venison, grouse and other game
Life and Style
fashionHealth concerns and 'pornified' perceptions have made women more conscious at the beach
Arts and Entertainment
tv
Sport
Ojo Onaolapo celebrates winning the bronze medal
commonwealth games
Arts and Entertainment
Rock band Led Zeppelin in the early 1970s
musicLed Zeppelin to release alternative Stairway To Heaven after 43 years
Arts and Entertainment
High-flyer: Chris Pratt in 'Guardians of the Galaxy'
filmHe was homeless in Hawaii when he got his big break. Now the comic actor Chris Pratt is Hollywood's new favourite action star
Sport
Van Gaal said that his challenge in taking over Bobby Robson's Barcelona team in 1993 has been easier than the task of resurrecting the current United side
footballA colourful discussion on tactics, the merits of the English footballer and rebuilding Manchester United
Life and Style
Sainsbury's could roll the lorries out across its whole fleet if they are successful
tech
Travel
The shipping news: a typical Snoozebox construction
travelSpending the night in a shipping container doesn't sound appealing, but mobile crash pads are popping up at the summer's biggest events
Arts and Entertainment
'Old Fashioned' will be a different kind of love story to '50 Shades'
film
Arts and Entertainment
Tracey Emin's 'My Bed' is returning to the Tate more than 15 years after it first caused shockwaves at the gallery
artTracey Emin's bed returns to the Tate after record sale
Arts and Entertainment
Smart mover: Peter Bazalgette
filmHow live cinema screenings can boost arts audiences
Environment
Neil Young performing at Hyde Park, London, earlier this month
environment
Independent
Travel Shop
the manor
Up to 70% off luxury travel
on city breaks Find out more
santorini
Up to 70% off luxury travel
on chic beach resorts Find out more
sardina foodie
Up to 70% off luxury travel
on country retreats Find out more
Latest stories from i100
Have you tried new the Independent Digital Edition apps?

ES Rentals

    Independent Dating
    and  

    By clicking 'Search' you
    are agreeing to our
    Terms of Use.

    iJobs Job Widget
    iJobs General

    Project Coordinator

    Competitive: The Green Recruitment Company: The Organisation: The Green Recrui...

    Project Manager (HR)- Bristol - Upto £400 p/day

    £350 - £400 per annum + competitive: Orgtel: Project Manager (specializing in ...

    Embedded Linux Engineer

    £40000 - £50000 per annum + competitive: Progressive Recruitment: Embedded Sof...

    Senior Hardware Design Engineer - Broadcast

    £50000 - £65000 per annum + Benefits: Progressive Recruitment: Working for a m...

    Day In a Page

    Save the tiger: The animals bred for bones on China’s tiger farms

    The animals bred for bones on China’s tiger farms

    The big cats kept in captivity to perform for paying audiences and then, when dead, their bodies used to fortify wine
    A former custard factory, a Midlands bog and a Leeds cemetery all included in top 50 hidden spots in the UK

    A former custard factory, a Midlands bog and a Leeds cemetery

    Introducing the top 50 hidden spots in Britain
    Ebola epidemic: Plagued by fear

    Ebola epidemic: Plagued by fear

    How a disease that has claimed fewer than 2,000 victims in its history has earned a place in the darkest corner of the public's imagination
    Chris Pratt: From 'Parks and Recreation' to 'Guardians of the Galaxy'

    From 'Parks and Recreation' to 'Guardians of the Galaxy'

    He was homeless in Hawaii when he got his big break. Now the comic actor Chris Pratt is Hollywood's new favourite action star
    How live cinema screenings can boost arts audiences

    How live cinema screenings can boost arts audiences

    Broadcasting plays and exhibitions to cinemas is a sure-fire box office smash
    Shipping container hotels: Pop-up hotels filling a niche

    Pop-up hotels filling a niche

    Spending the night in a shipping container doesn't sound appealing, but these mobile crash pads are popping up at the summer's biggest events
    Native American headdresses are not fashion accessories

    Feather dust-up

    A Canadian festival has banned Native American headwear. Haven't we been here before?
    Boris Johnson's war on diesel

    Boris Johnson's war on diesel

    11m cars here run on diesel. It's seen as a greener alternative to unleaded petrol. So why is London's mayor on a crusade against the black pump?
    5 best waterproof cameras

    Splash and flash: 5 best waterproof cameras

    Don't let water stop you taking snaps with one of these machines that will take you from the sand to meters deep
    Louis van Gaal interview: Manchester United manager discusses tactics and rebuilding after the David Moyes era

    Louis van Gaal interview

    Manchester United manager discusses tactics and rebuilding after the David Moyes era
    Will Gore: The goodwill shown by fans towards Alastair Cook will evaporate rapidly if India win the series

    Will Gore: Outside Edge

    The goodwill shown by fans towards Alastair Cook will evaporate rapidly if India win the series
    The children were playing in the street with toy guns. The air strikes were tragically real

    The air strikes were tragically real

    The children were playing in the street with toy guns
    Boozy, ignorant, intolerant, but very polite – The British, as others see us

    Britain as others see us

    Boozy, ignorant, intolerant, but very polite
    How did our legends really begin?

    How did our legends really begin?

    Applying the theory of evolution to the world's many mythologies
    Watch out: Lambrusco is back on the menu

    Lambrusco is back on the menu

    Naff Seventies corner-shop staple is this year's Aperol Spritz